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The cytotoxic properties of granzymes are well established, though recent publications suggest additional roles for
granzymes in immunity. We demonstrated that granzymes can act as regulators of cross-presentation by dendritic
cells by inducing critical “eat-me” signals on the dying tumor cell, resulting in efficient phagocytosis of cell-associated
tumor antigen.
One of the key mechanisms used by cells
of the immune system to eliminate cancer
cells is their recognition by cytotoxic
lymphocytes (CL), which comprise natural
killer cells as part of the innate, and
cytotoxic T lymphocytes (CTL) within the
adaptive immune system. Upon recog-
nition, CL kill tumor cells by either
engaging death receptors or by granule
exocytosis, whereby proteases are released
into the immune synapse, cross the target
cell membrane through perforin pores
and finally induce apoptosis by cleaving
their various substrates. The key death-
inducing effector molecules are thought
to be granzyme A (GrA) and granzyme B
(GrB).
1 The direct cytotoxicity of gran-
zymes is typically regarded as an important
anti-tumor function in itself, however the
ultimate fate of tumor cells killed via
granzymes has never, until recently, been
explored in detail. In our work, we
demonstrated a critical role for granzymes
in anti-tumor immunity by showing that
they induce pro-phagocytic signals on the
dying tumor cell.
2
Tumor cells killed by GrAB-sufficient
CL show morphological signs of apoptosis
such as rounding, blebbing, lifting from
the substrate and chromatin condensation.
3
Furthermore, time-lapse microscopy con-
firmed the early exposure of phosphatidyl-
serine (PS) followed some time later by
loss of membrane integrity, indicating
secondarynecrosis. Incontrast,CLdeficient
for GrAB showed morphological charac-
teristics of apoptosis but lacked early PS
exposure until the cell membrane became
permeable for a DNA intercalating dye.
3 As
PS is regarded as one of the most critical
signal for uptake of apoptotic cells, we
explored the functional significance of
tumor cell death in the absence or presence
of GrAB. We used GrAB-sufficient or
-deficient CTL to kill antigen-specific
tumor cells carrying the model antigen
ovalbumin (OVA) and co-cultured dying
tumor cells with dendritic cells (DC).
2 We
found that CD8a
+ DC showed a marked
reduction in OVA cross-presentation in
vitro and in vivo when exposed to tumor
cells killed in the absence of GrAB. By
contrast, the absence or presence of GrAB
had no effect on the expression of activation
makers and secretion of cytokines by the
CD8a
+ DC. Nevertheless, the MHC class I
molecules of CD8a
+ DC were significantly
occupied by the OVA peptide SIINFEKL
only when the DC were co-cultured with
tumor cells killed by GrAB-sufficient CTL.
Finally, we were able to pin down the
impaired cross-presentation by DC to a
marked reduction of phagocytosis of the
dying tumor cells. By using Annexin V to
block PS, we found that PS per se is not
critical for tumor cell uptake by DC,
confirming previous studies using UV-
irradiated tumor cells.
4 From these experi-
ments,wefurtherconcludedthatgranzymes
induce other pro-phagocytic “eat-me” sig-
nals apart from PS on the outer membrane
of dying tumor cells (Fig.1).
2
Our findings have implications for vari-
ous aspects of the immune response against
cancerous cells. First and most obviously,
we showed that granule-mediated cell
death induces an immunogenic form of
cell death leading subsequently to greatly
amplified tumor antigen-specific effector
responses. Immunogenic cell death has
been described for several cell death
inducing agents such as chemotherapeutic
drugs that can act either by facilitating
engulfment by antigen-presenting cells,
or by releasing activating signals such as
ATP or HMGB-1,
5 resulting in anti-tumor
immunity. Furthermore, once an adaptive
immune response is induced to one par-
ticular tumor antigen, the early phase of
CTL killing may result in epitope spreading
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and consequently, a broadened adaptive T
cell response to additional tumor-associated
antigens. In human cancer patients, various
therapies such as vaccination or adoptive T
cell therapy should benefit from epitope
spreading and therefore counteract tumor
immune escape caused by the selective loss
of the dominant tumor antigen.
6 However,
similar studies with human tumor cells
killed exclusively via granule exocytosis are
needed to confirm our results in a human
setting, as mouse and human GrB show
subtle but important differences in sub-
strate preference.
7
Futhermore, it is well established that
tumor cells can become resistant to receptor
mediated apoptosis via TNFa,F a s Lo r
TRAIL by downregulating extracellular
receptors or by upregulating cytoplasmatic
expression of inhibitors such as dominant-
negative Fas-associated death domain
(FADD) or intracellular FADD-like inhi-
bitory protein (FLIP).
8 In such instances,
the elimination of tumor cells relies solely
on the perforin/granzyme pathway. Under
these conditions we postulate that the lack
of expression of GrAB by CL or the
additional expression of intrinsic granzyme
inhibitors (serpins) by the tumor would
result in markedly impaired phagocytosis,
and therefore, reduced cross-presentation of
tumor antigen leading to a poor anti-tumor
immunity.
Our study contributed a novel function
for granzymes to the constantly growing
body of evidence that granzymes have
many more functions in addition to their
well-established role in direct, perforin-
dependent cytotoxicity. Recently, GrA was
found to induce pro-inflammatory cyto-
kine release in myeloid cells through a
perforin-dependent mechanism that also
extended to granzyme M in a TLR-4
dependent endotoxic shock model.
9,10
Our study revealed that granzyme-
mediated cell death plays a significant
role critical for the induction of immu-
nity to tumor antigen, by regulating the
phagocytic uptake of dying tumor cells.
However, the specific nature of the
phagocytic signal remains to be elucidated;
its identification will also have signifi-
cant impact on studies in dendritic cell
biology.
Figure1. Cell-mediated killing of tumor cells by wild-type cytotoxic lymphocytes (WT CL) via granzymes A and B (GrAB) results in the exposure of yet
unknown pro-phagocytic “eat-me” signals in addition to phosphatidlyserine exposure (PS). The CD8a
+ DC engulf dying tumor cells and cross-present
tumor antigen to naïve cytotoxic T lymphocytes (CTL), inducing in turn an adaptive immune response against the tumor. However, tumor cell death in
the absence of GrAB (GrAB
2/2 CL) lacks PS exposure and other pro-phagocytic “eat-me” signals leading to reduced phagocytosis, cross-presentation and
subsequent induction of tumor specific CTL.
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